As compared with D2 lymphadenectomy alone, treatment with D2 lymphadenectomy plus PAND does not improve the survival rate in curable gastric cancer. (ClinicalTrials.gov number, NCT00149279.)

Read Full Paperexternally

Bookmark

View Full Paper

Bookmark

View Full Paper

Cite This Study

Sasako et al. (Wed,) studied this question.

synapsesocial.com/papers/69dd32eda6ead7ee0940c620 https://doi.org/https://doi.org/10.1056/nejmoa0707035

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Nodal dissection for patients with gastric cancer: a randomised controlled trial2006 · 625 citations
2TNM Classification of Malignant Tumours1987 · 16,123 citations
3Impact of Hospital Volume on Operative Mortality for Major Cancer Surgery1998 · 1,667 citations
4Hepatogastroenterology2011 · 1,260 citations
5Gastric cancer epidemiology and risk factors2003 · 755 citations

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Nodal dissection for patients with gastric cancer: a randomised controlled trial2006 · 625 citations
2TNM Classification of Malignant Tumours1987 · 16,123 citations
3Impact of Hospital Volume on Operative Mortality for Major Cancer Surgery1998 · 1,667 citations
4Hepatogastroenterology2011 · 1,260 citations
5Gastric cancer epidemiology and risk factors2003 · 755 citations